Oleate alters the immune response in non-small cell lung adenocarcinoma through regulation of HMGB1 release

被引:1
|
作者
Cole-Skinner, Breanna [1 ]
Andre, Nicole M. [2 ]
Blankenheim, Zachary [3 ]
Root, Kate M. [3 ]
Jafri, Kisa [2 ]
Simmons Jr, Glenn E. [2 ]
机构
[1] Univ Missouri, Dept Mol Microbiol & Immunol, Columbia, MO USA
[2] Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14850 USA
[3] Univ Minnesota, Sch Med, Dept Biomed Sci, Duluth, MN USA
关键词
HMGB1 (high mobility group box 1); lung cancer; tumor microenvironment; fatty acid; immunotherapy; COA-DESATURASE; 1; LIPID-METABOLISM; DOWN-REGULATION; PROTEIN HMGB1; CANCER; DIFFERENTIATION; ACETYLATION; PROGRESSION; SURVIVAL; GROWTH;
D O I
10.3389/fcell.2024.1348707
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: Cancer cell evasion of the immune response is critical to cancer development and metastases. Clinicians' ability to kickstart the immune system to target these rogue cells is an ever-growing area of research and medicine. This study delved into the relationship between lipid metabolism, High Mobility Group Box 1 protein (HMGB1)-a pro-inflammatory damage-associated molecular pattern protein-and immune regulation within non-small cell lung adenocarcinoma (NSCLC).Method: To address this question, we used a combination of proteomics, molecular biology, and bioinformatic techniques to investigate the relationship between fatty acids and immune signals within NSCLC.Results: We found that the expression of stearoyl CoA desaturase 1 (SCD1) was decreased in NSCLC tumors compared to normal tissues. This emphasized the critical role of lipid metabolism in tumor progression. Interestingly, monounsaturated fatty acid (MUFA) availability affected the expression of programmed death ligand-1 (PD-L1), a pivotal immune checkpoint target in lung cancer cells and immune cells, as well as HMGB1, suggesting a novel approach to modulating the immune response. This study uncovered a complex interplay between SCD1, PD-L1, and HMGB1, influencing the immunological sensitivity of tumors.Conclusion: Our work underscores the critical importance of understanding the intricate relationships between lipid metabolism and immune modulation to develop more effective NSCLC treatments and personalized therapies. As we continue to explore these connections, we hope to contribute significantly to the ever-evolving field of cancer research, improving patient outcomes and advancing precision medicine in NSCLC.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Immune Signatures of Non-Small Cell Lung Cancer
    Green, Susan
    Dawe, David E.
    Banerji, Shantanu
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (06) : 913 - 915
  • [32] The Impact of Intratumoral Glucocorticoid Synthesis Through 11β Hydroxysteroid Dehydrogenase 1 on the Intratumoral Immune Microenvironment in Non-Small Cell Lung Carcinoma: A New Marker for Predicting Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Carcinoma
    Saito, Ryoko
    Miki, Yasuhiro
    Abe, Jiro
    Inoue, Chihiro
    Sato, Ikuro
    Sasano, Hironobu
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1813 - 1815
  • [33] Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells
    Ma, Ying
    Kang, Shirong
    Wu, Xu
    Han, Bateer
    Jin, Zhiyong
    Guo, Zhanlin
    TUMORI JOURNAL, 2018, 104 (05): : 338 - 343
  • [34] The Impact of Intratumoral Glucocorticoid Synthesis Through 11β Hydroxysteroid Dehydrogenase 1 on the Intratumoral Immune Microenvironment in Non-Small Cell Lung Carcinoma: A New Marker for Predicting Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Carcinoma
    Saito, Ryoko
    Miki, Yasuhiro
    Abe, Jiro
    Inoue, Chihiro
    Sato, Ikuro
    Sasano, Hironobu
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1813 - 1815
  • [35] A Functional Pharmacogenetic Screen in Non-small Cell Lung Adenocarcinoma
    de la Cruz, F. Fece
    Smida, M.
    Nijman, S. M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S234 - S234
  • [36] Immune cytolysis induces HMGB1 release through a partially caspase dependent apoptotic pathway
    Ito, Norimasa
    Demarco, Richard A.
    Mailliard, Robbie B.
    Han, Jie
    Rabinowich, Hannah
    Kalinski, Pawel
    Stolz, Donna B.
    Zeh, Herbert J.
    Lotze, Michael T.
    JOURNAL OF IMMUNOTHERAPY, 2006, 29 (06) : 681 - 681
  • [37] Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Alfranca, Yolanda Lage
    Garcia, Maria Eugenia Olmedo
    Rueda, Ana Gomez
    Ballesteros, Pablo Alvarez
    Rodriguez, Diana Rosero
    Velasco, Marisa Torres
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (11)
  • [38] Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer
    Hallqvist, Andreas
    Rohlin, Anna
    Raghavan, Sukanya
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (06)
  • [39] Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting
    Mountzios, Giannis
    Linardou, Helena
    Kosmidis, Paris
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (14)
  • [40] The Influence of Neoadjuvant Chemotherapy, on Immune Response Profile in Non-Small Cell Lung Carcinomas
    Parra, Edwin
    Rodriguez-Canales, Jaime
    Behrens, Carmen
    Jiang, Mei
    Pataer, Apar
    Correa, Arelene
    Swisher, Stephen
    Sepesi, Boris
    Weissferdt, Annikka
    Kalhor, Neda
    William, William, Jr.
    Lee, Jack
    Heymach, John
    Moran, Cesar
    Zhang, Jianjun
    Gibbons, Don Lynn
    Wistuba, Ignacio
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S323 - S324